SRD5A2 V89L polymorphism and prostate cancer risk: A meta-analysis
BACKGROUND Increasing studies investigating the association between steroid 5‐alpha reductase type II gene polymorphism at codon 89 (SRD5A2 V89L) and susceptibility to prostate cancer (PCa) confer inconsistent results. To precisely estimate the relationship with more statistical power, a meta‐analys...
Gespeichert in:
| Veröffentlicht in: | The Prostate 2010-02, Vol.70 (2), p.170-178 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 178 |
|---|---|
| container_issue | 2 |
| container_start_page | 170 |
| container_title | The Prostate |
| container_volume | 70 |
| creator | Wang, Chunyang Tao, Weiyang Chen, Qiyin Hu, Hailong Wen, Xiao-Yan Han, Ruifa |
| description | BACKGROUND
Increasing studies investigating the association between steroid 5‐alpha reductase type II gene polymorphism at codon 89 (SRD5A2 V89L) and susceptibility to prostate cancer (PCa) confer inconsistent results. To precisely estimate the relationship with more statistical power, a meta‐analysis was performed.
METHODS
A comprehensive search was conducted to identify all case–control studies investigating such an association. Odds ratio (OR) and its 95% confidence interval (CI) were used to evaluate the size effect.
RESULTS
Twenty‐five eligible reports were identified including 8,615 cases/9,089 controls in 33 comparisons. In overall analysis, no significant associations were found in all genetic models. Subgroup analyses by ethnicity revealed that small excess PCa risks were observed in dominant model (OR, 1.11; 95% CI, 1.03–1.19 for (LL + VL) vs. VV; P |
| doi_str_mv | 10.1002/pros.21050 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_pros_21050</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>PROS21050</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3110-a410d0e698d8f38686621891a5029c1a9858807fb159f4f4dc218ffb3544e37e3</originalsourceid><addsrcrecordid>eNp90M1PwjAUAPDGaBQ_Lv4BZhcvJtP32nVtvSEqmqAYQDk2ZWvjdIOlxSj_vUMQb57e4f3eJyHHCOcIQC9qPwvnFIHDFmkhKBEDJHybtIAKiBNkYo_sh_AG0HCgu2QPlUghZdgiV8PBNW_T6EWqXlTPykU18_VrEarITPNo2Xlu5jbKzDSzPvJFeL-M2lFl5yY2U1MuQhEOyY4zZbBH63hAnm9vRp27uNfv3nfavThjiBCbBCEHmyqZS8dkKtOUolRoOFCVoVGSSwnCTZArl7gkz5q0cxPGk8QyYdkBOVv1zZqtgrdO176ojF9oBL18hF6uq38e0eCTFa4_JpXN_-j68gacroEJmSmdby4swsZRShUVSjQOV-6zKO3in5H6adAf_g6PVzVFmNuvTY3x7zoVTHA9fuxqzsfdEXYedMK-AWnege4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>SRD5A2 V89L polymorphism and prostate cancer risk: A meta-analysis</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Wang, Chunyang ; Tao, Weiyang ; Chen, Qiyin ; Hu, Hailong ; Wen, Xiao-Yan ; Han, Ruifa</creator><creatorcontrib>Wang, Chunyang ; Tao, Weiyang ; Chen, Qiyin ; Hu, Hailong ; Wen, Xiao-Yan ; Han, Ruifa</creatorcontrib><description>BACKGROUND
Increasing studies investigating the association between steroid 5‐alpha reductase type II gene polymorphism at codon 89 (SRD5A2 V89L) and susceptibility to prostate cancer (PCa) confer inconsistent results. To precisely estimate the relationship with more statistical power, a meta‐analysis was performed.
METHODS
A comprehensive search was conducted to identify all case–control studies investigating such an association. Odds ratio (OR) and its 95% confidence interval (CI) were used to evaluate the size effect.
RESULTS
Twenty‐five eligible reports were identified including 8,615 cases/9,089 controls in 33 comparisons. In overall analysis, no significant associations were found in all genetic models. Subgroup analyses by ethnicity revealed that small excess PCa risks were observed in dominant model (OR, 1.11; 95% CI, 1.03–1.19 for (LL + VL) vs. VV; P < 0.01; Pheterogeneity = 0.49) and L allele frequency comparison (OR, 1.09; 1.03–1.15 for L allele frequency; P < 0.01; Pheterogeneity = 0.07) in Europeans. Meanwhile, SRD5A2 V89L polymorphism was significantly associated with an increased PCa risk in men aged ≤65 under the co‐dominant (OR, 1.70; 95% CI, 1.09–2.66 for LL vs. VV; P = 0.02; Pheterogeneity = 0.31) and recessive (OR, 1.75; 95% CI, 1.14–2.68 for LL vs. (VV + VL); P = 0.01; Pheterogeneity = 0.12) models. However, no significant associations were found in Asians and Africans.
CONCLUSIONS
Our study suggests SRD5A2 V89L polymorphism could play a low‐penetrant role in PCa risk among Europeans and individuals younger than 65 years. Additional well‐designed studies are warranted to validate these findings. Prostate 70: 170–178, 2010. ©2009 Wiley‐Liss, Inc.</description><identifier>ISSN: 0270-4137</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/pros.21050</identifier><identifier>PMID: 19760631</identifier><identifier>CODEN: PRSTDS</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>3-Oxo-5-alpha-Steroid 4-Dehydrogenase - genetics ; Biological and medical sciences ; Case-Control Studies ; Cyclophosphamide - analogs & derivatives ; Genetic Predisposition to Disease ; Gynecology. Andrology. Obstetrics ; Humans ; Male ; Male genital diseases ; Medical sciences ; meta-analysis ; Middle Aged ; Nephrology. Urinary tract diseases ; Polymorphism, Genetic ; prostatic neoplasms ; Prostatic Neoplasms - ethnology ; Prostatic Neoplasms - genetics ; single nucleotide polymorphism ; SRD5A2 ; susceptibility ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>The Prostate, 2010-02, Vol.70 (2), p.170-178</ispartof><rights>Copyright © 2009 Wiley‐Liss, Inc.</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3110-a410d0e698d8f38686621891a5029c1a9858807fb159f4f4dc218ffb3544e37e3</citedby><cites>FETCH-LOGICAL-c3110-a410d0e698d8f38686621891a5029c1a9858807fb159f4f4dc218ffb3544e37e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpros.21050$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpros.21050$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22292797$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19760631$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Chunyang</creatorcontrib><creatorcontrib>Tao, Weiyang</creatorcontrib><creatorcontrib>Chen, Qiyin</creatorcontrib><creatorcontrib>Hu, Hailong</creatorcontrib><creatorcontrib>Wen, Xiao-Yan</creatorcontrib><creatorcontrib>Han, Ruifa</creatorcontrib><title>SRD5A2 V89L polymorphism and prostate cancer risk: A meta-analysis</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>BACKGROUND
Increasing studies investigating the association between steroid 5‐alpha reductase type II gene polymorphism at codon 89 (SRD5A2 V89L) and susceptibility to prostate cancer (PCa) confer inconsistent results. To precisely estimate the relationship with more statistical power, a meta‐analysis was performed.
METHODS
A comprehensive search was conducted to identify all case–control studies investigating such an association. Odds ratio (OR) and its 95% confidence interval (CI) were used to evaluate the size effect.
RESULTS
Twenty‐five eligible reports were identified including 8,615 cases/9,089 controls in 33 comparisons. In overall analysis, no significant associations were found in all genetic models. Subgroup analyses by ethnicity revealed that small excess PCa risks were observed in dominant model (OR, 1.11; 95% CI, 1.03–1.19 for (LL + VL) vs. VV; P < 0.01; Pheterogeneity = 0.49) and L allele frequency comparison (OR, 1.09; 1.03–1.15 for L allele frequency; P < 0.01; Pheterogeneity = 0.07) in Europeans. Meanwhile, SRD5A2 V89L polymorphism was significantly associated with an increased PCa risk in men aged ≤65 under the co‐dominant (OR, 1.70; 95% CI, 1.09–2.66 for LL vs. VV; P = 0.02; Pheterogeneity = 0.31) and recessive (OR, 1.75; 95% CI, 1.14–2.68 for LL vs. (VV + VL); P = 0.01; Pheterogeneity = 0.12) models. However, no significant associations were found in Asians and Africans.
CONCLUSIONS
Our study suggests SRD5A2 V89L polymorphism could play a low‐penetrant role in PCa risk among Europeans and individuals younger than 65 years. Additional well‐designed studies are warranted to validate these findings. Prostate 70: 170–178, 2010. ©2009 Wiley‐Liss, Inc.</description><subject>3-Oxo-5-alpha-Steroid 4-Dehydrogenase - genetics</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Cyclophosphamide - analogs & derivatives</subject><subject>Genetic Predisposition to Disease</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Male</subject><subject>Male genital diseases</subject><subject>Medical sciences</subject><subject>meta-analysis</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Polymorphism, Genetic</subject><subject>prostatic neoplasms</subject><subject>Prostatic Neoplasms - ethnology</subject><subject>Prostatic Neoplasms - genetics</subject><subject>single nucleotide polymorphism</subject><subject>SRD5A2</subject><subject>susceptibility</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0270-4137</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90M1PwjAUAPDGaBQ_Lv4BZhcvJtP32nVtvSEqmqAYQDk2ZWvjdIOlxSj_vUMQb57e4f3eJyHHCOcIQC9qPwvnFIHDFmkhKBEDJHybtIAKiBNkYo_sh_AG0HCgu2QPlUghZdgiV8PBNW_T6EWqXlTPykU18_VrEarITPNo2Xlu5jbKzDSzPvJFeL-M2lFl5yY2U1MuQhEOyY4zZbBH63hAnm9vRp27uNfv3nfavThjiBCbBCEHmyqZS8dkKtOUolRoOFCVoVGSSwnCTZArl7gkz5q0cxPGk8QyYdkBOVv1zZqtgrdO176ojF9oBL18hF6uq38e0eCTFa4_JpXN_-j68gacroEJmSmdby4swsZRShUVSjQOV-6zKO3in5H6adAf_g6PVzVFmNuvTY3x7zoVTHA9fuxqzsfdEXYedMK-AWnege4</recordid><startdate>20100201</startdate><enddate>20100201</enddate><creator>Wang, Chunyang</creator><creator>Tao, Weiyang</creator><creator>Chen, Qiyin</creator><creator>Hu, Hailong</creator><creator>Wen, Xiao-Yan</creator><creator>Han, Ruifa</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20100201</creationdate><title>SRD5A2 V89L polymorphism and prostate cancer risk: A meta-analysis</title><author>Wang, Chunyang ; Tao, Weiyang ; Chen, Qiyin ; Hu, Hailong ; Wen, Xiao-Yan ; Han, Ruifa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3110-a410d0e698d8f38686621891a5029c1a9858807fb159f4f4dc218ffb3544e37e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>3-Oxo-5-alpha-Steroid 4-Dehydrogenase - genetics</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Cyclophosphamide - analogs & derivatives</topic><topic>Genetic Predisposition to Disease</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Male</topic><topic>Male genital diseases</topic><topic>Medical sciences</topic><topic>meta-analysis</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Polymorphism, Genetic</topic><topic>prostatic neoplasms</topic><topic>Prostatic Neoplasms - ethnology</topic><topic>Prostatic Neoplasms - genetics</topic><topic>single nucleotide polymorphism</topic><topic>SRD5A2</topic><topic>susceptibility</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Chunyang</creatorcontrib><creatorcontrib>Tao, Weiyang</creatorcontrib><creatorcontrib>Chen, Qiyin</creatorcontrib><creatorcontrib>Hu, Hailong</creatorcontrib><creatorcontrib>Wen, Xiao-Yan</creatorcontrib><creatorcontrib>Han, Ruifa</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Chunyang</au><au>Tao, Weiyang</au><au>Chen, Qiyin</au><au>Hu, Hailong</au><au>Wen, Xiao-Yan</au><au>Han, Ruifa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SRD5A2 V89L polymorphism and prostate cancer risk: A meta-analysis</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>2010-02-01</date><risdate>2010</risdate><volume>70</volume><issue>2</issue><spage>170</spage><epage>178</epage><pages>170-178</pages><issn>0270-4137</issn><eissn>1097-0045</eissn><coden>PRSTDS</coden><abstract>BACKGROUND
Increasing studies investigating the association between steroid 5‐alpha reductase type II gene polymorphism at codon 89 (SRD5A2 V89L) and susceptibility to prostate cancer (PCa) confer inconsistent results. To precisely estimate the relationship with more statistical power, a meta‐analysis was performed.
METHODS
A comprehensive search was conducted to identify all case–control studies investigating such an association. Odds ratio (OR) and its 95% confidence interval (CI) were used to evaluate the size effect.
RESULTS
Twenty‐five eligible reports were identified including 8,615 cases/9,089 controls in 33 comparisons. In overall analysis, no significant associations were found in all genetic models. Subgroup analyses by ethnicity revealed that small excess PCa risks were observed in dominant model (OR, 1.11; 95% CI, 1.03–1.19 for (LL + VL) vs. VV; P < 0.01; Pheterogeneity = 0.49) and L allele frequency comparison (OR, 1.09; 1.03–1.15 for L allele frequency; P < 0.01; Pheterogeneity = 0.07) in Europeans. Meanwhile, SRD5A2 V89L polymorphism was significantly associated with an increased PCa risk in men aged ≤65 under the co‐dominant (OR, 1.70; 95% CI, 1.09–2.66 for LL vs. VV; P = 0.02; Pheterogeneity = 0.31) and recessive (OR, 1.75; 95% CI, 1.14–2.68 for LL vs. (VV + VL); P = 0.01; Pheterogeneity = 0.12) models. However, no significant associations were found in Asians and Africans.
CONCLUSIONS
Our study suggests SRD5A2 V89L polymorphism could play a low‐penetrant role in PCa risk among Europeans and individuals younger than 65 years. Additional well‐designed studies are warranted to validate these findings. Prostate 70: 170–178, 2010. ©2009 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>19760631</pmid><doi>10.1002/pros.21050</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0270-4137 |
| ispartof | The Prostate, 2010-02, Vol.70 (2), p.170-178 |
| issn | 0270-4137 1097-0045 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_pros_21050 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | 3-Oxo-5-alpha-Steroid 4-Dehydrogenase - genetics Biological and medical sciences Case-Control Studies Cyclophosphamide - analogs & derivatives Genetic Predisposition to Disease Gynecology. Andrology. Obstetrics Humans Male Male genital diseases Medical sciences meta-analysis Middle Aged Nephrology. Urinary tract diseases Polymorphism, Genetic prostatic neoplasms Prostatic Neoplasms - ethnology Prostatic Neoplasms - genetics single nucleotide polymorphism SRD5A2 susceptibility Tumors Tumors of the urinary system Urinary tract. Prostate gland |
| title | SRD5A2 V89L polymorphism and prostate cancer risk: A meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T02%3A55%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SRD5A2%20V89L%20polymorphism%20and%20prostate%20cancer%20risk:%20A%20meta-analysis&rft.jtitle=The%20Prostate&rft.au=Wang,%20Chunyang&rft.date=2010-02-01&rft.volume=70&rft.issue=2&rft.spage=170&rft.epage=178&rft.pages=170-178&rft.issn=0270-4137&rft.eissn=1097-0045&rft.coden=PRSTDS&rft_id=info:doi/10.1002/pros.21050&rft_dat=%3Cwiley_cross%3EPROS21050%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/19760631&rfr_iscdi=true |